Attorney Docket No.: 10391.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Olsen et al. Confirmation No: 4566

Serial No.: 10/797,393 Group Art Unit: 1651

Filed: March 10, 2004 Examiner: Hanley

For: Alcohol Product Processes

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

In accordance with 37 C.F.R. 1.58, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.58, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be constitude as a representation that no other material references than those listed exist or that a search has been confuded.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed after the period set forth in 37 CFR 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p). Please charge the fee, estimated to be \$180.00, to Novozymes North America, Inc., Denosit Account No. 50-1701.

Respectfully submitted,

Date: March 2, 2007

/Elias Lambiris, Reg. # 33728/ Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097